3 Houston innovators to know this week

who's who

This week's innovators to know are focused on bringing startup programming and venture capital to Houston. Courtesy photos

This past week has been full of exciting innovation news in Houston — from big fundraising round closings to a new unicorn coming out of the Bayou City.

Houston innovators to know this week include a new program director for Houston's newest startup accelerator, a venture capital fund leader, and more.

Eléonore Cluzel, program director of gBETA Houston program as director

Courtesy of gBETA Houston

Houston's newest accelerator program, gBETA, named its new local leader. Eléonore Cluzel will lead the gBETA Houston program as director, and will be the point person for the program in the region for the two annual cohorts. Previously, Cluzel worked for Business France mentoring French startups and small businesses. In her new position, she says she's excited to support founders across all industries and foster innovation.

"We're adding another resource for local founders to grow their startups and to raise money, and not have to move to Silicon Valley to do it," she says. "We will also serve as a connector, introducing founders to mentors and investors within the community and across gener8tor broader network." Click here to read more.

Sandy Wallis, managing director of the HX Venture Fund

Courtesy of Sandy Wallis

After 20 years in the venture capital world, Sandy Guitar Wallis has seen the evolution of investing — on both coasts and here in Houston as well. Now, as managing director of the HX Venture Fund, Wallis leads the fund of funds that's investing in VCs around the country in order to bring investment to Houston.

"We have raised a fund of funds with the HX Venture Fund, and we're deploying that capital across probably 10 venture capital funds over time," Wallis explains on the most recent episode of the Houston Innovators Podcast. "Each one of those funds, will invest in 15 to 20 underlying private companies. So, at the end of the day, HX Venture Fund 1 will have exposure to 10 VC funds, as an example, and — by virtue of those investments — maybe 300 private companies." Click here to read more.

James Y. Lancaster, Texas branch manager for Arkansas-based VIC Technology Venture Development

Photo courtesy of VIC

Startups fail — and there are a number of reasons why that is. James Y. Lancaster, who serves as Texas branch manager for Arkansas-based VIC Technology Venture Development, writes in a guest column for InnovationMap about the second most common reason for startup failure: funding.

"A key part of the startup CEO's job is to understand how much total cash remains on hand and whether it is enough to carry the startup towards a milestone that can lead to successful financing as well as a positive cash flow," Lancaster writes. "Just as important is how to allocate their time and efforts to the fundraising process along the way." Click here to read more.

The second most common reason for startup failure is running out of funds. A Texas expert has tips for avoiding that downfall. Getty Images

Failing to fundraise can be the downfall of Houston startups — here's what you need to know

Guest column

Startups are pulling outsized financing rounds and debt acquisitions at an unprecedented rate despite the high 80 percent failure rate of startups overall. Among the three primary reasons why startups tend to fail, running out of cash falls in the number two spot on the list at 29 percent — following no market need.

But startups need to recognize that their time and a strategic fundraising effort are tied together as critical resources to allocate properly to drive their fundraising efforts.

Despite a multitude of ideas and approaches in the pursuit of the very elusive product-market fit and monetization, the majority of startups fail to raise funds or run out of cash after initial fundraising success. For the startup to be successful, it is imperative that funds, finances, and related resources are allocated productively and precisely.

A key part of the startup CEO's job is to understand how much total cash remains on hand and whether it is enough to carry the startup towards a milestone that can lead to successful financing as well as a positive cash flow. Just as important is how to allocate their time and efforts to the fundraising process along the way.

A constant battle

For starters, valuations of a startup do not change linearly over time. Simply because it was twelve months since raising a series A round does not mean that it will be easier to raise more money or be ready for a step-up in valuation. To reach an increase in valuation, a company must achieve certain key milestones that are relevant to showing progress to market and in most investors eye's progress towards monetization.

It is important to understand what potential investors think is worthy of a step up, but generally valuation is pretty flat in between inflection points where key milestones are reached that earn a big increase.

Active vs. passive investment pursuits

Given that it often takes six to nine months and two-thirds of a CEO's time during a major round of fundraising, optimally you should align progress points into major milestones where efforts can be concentrated for fundraising success approaching the inflection points. That does not mean that the CEO can ignore fundraising in between those major milestones, but should think about waves of active and passive fundraising activities.

Active fundraising is obvious, which is the typical efforts to craft a pitch, meet with investors, nurture investor prospects into lead and following investor types. Most of the effort should be put into the early investors that will lead the round as the first checks are always the hardest.

From my experience rounds develop their own momentum when reaching about 40 percent of their target and even more when reaching 60 percent as long as the prospective investor pool is large enough. However, the CEO cannot ignore the company's progress while the raise is actively underway, as they will typically meet with prospective investors multiple times who will want to hear about progress each time.

Passive fundraising is less obvious, which happens in the gaps in between active fundraising where one round closes and before the next round starts. The primary passive activity is general investor networking, where the CEO should be out expanding their network, meeting new prospects and trying to identify the mostly likely early investors or best fit for the company.

I'm not suggesting this is really a passive activity, as it takes a lot of work. But this should be an ongoing between rounds. This passive effort gives the CEO a chance to put most of their emphasis on the progress of the company to the next milestones, but avoids a cold start to the next fundraising round.

Regardless, there are two best practices in this passive mode. First, use networking techniques to identify good prospective investors for your company and two to work on getting referrals to investors well before an actual fundraising round is open. Getting a referral is obviously to your advantage, because it takes you out of cold-calling mode that has a low success rate.

Meeting an investor while you are not fundraising takes the pressure off both the CEO and investor and gives them a chance to get to know each other personally. Again, many will not be your round leaders or champions to other investors, but this lower pressure effort gives investors a chance to listen and reach out to potential experts in their networks to validate the problem and your solution.

With the relationship established and your solution validation received, moving to an active discussion about investment comes more naturally as well as targeting of the best lead investor candidates leading to due diligence, negotiation and closing the funds.

Within a technology development firm like my firm, VIC, we have the benefit of "always-on" VIC Investor Network that we are constantly working to refresh and expand. Because of our large portfolio, seventeen companies at the time of writing this, there is a good chance that almost any life science investor can find something that suits their interest, experience, or passions.

Each member of the firm can allocate their time between active and passive efforts for the companies they are most closely involved with while still providing a wide portfolio of other companies that might be of interest to a prospective investor. Even with a portfolio of companies, the same concepts of active and passive efforts apply.

------

James Y. Lancaster is the Texas branch manager for Arkansas-based VIC Technology Venture Development. Lancaster, who lives in College Station, oversees business there, in Dallas, and in Houston.

The biggest reason startups fail is because of no market need. Emilija Manevska/Getty Images

Why you need to prevent 'expert syndrome' and find a market need for your startup to succeed

Guest column

It's a brave new world. It's an era of hot IPO's, next-generation technological disruptions, Silicon Valley tech-storms, and many startups that eventually nosedive. Many startups believe that they are creating the next best thing, but in reality, more than 80 percent of the startups fail on a global scale.

These are staggering numbers as the world is evolving, and the job market is saturating exponentially, giving to the rise of startups and entrepreneurial ventures. Nowadays, it's easy to get caught up in the endless stories of startup successes, but in actuality, startup failures are way more common that startup successes in accord with data from CB Insights.

According to the surveys by CB Insights analysts and researchers, more than 70 percent of upstart tech companies fail, and their counterparts the 'consumer hardware startups' are prone to failure with 97 percent ultimately dying or becoming "zombies." Let's talk about why startups and businesses fail. One of the significant factors that cause startups to fail miserably is that there's no market need.

Preventing 'expert syndrome'

Startups can run into the problem of their being little or no market need for the product or service they are providing. Startup founders tend to overrate and overestimate themselves and underrate the more experienced people around them. This is known as 'expert syndrome,' and it is one of the contributing reasons why many startups tend to fail and nosedive.

Ignorant individuals are often bursting with escapism, unrealistic expectations and grandeur emotions, which may cause their businesses to fall out. The actual feeling that you are in control combined with an idealistic inevitability that there is market need for the creator's product or service can lead to inevitable failure.

Expert syndrome is recognized in the field of psychology as the Dunning-Kruger effect; cognitive bias of superiority in the mind of an individual that believes their knowledge is greater than it is. This can also result in unrealistic expectations for otherwise relatively small impact incremental innovations.

As an MBA, I have seen this in myself over the years (admittedly often in hindsight) and in waves of fresh MBAs trying to turn their class project business plan into a real business. However, it is not exclusive to MBAs as any domain experts' true knowledge could be limited by their perspective and experience of a given situation. On the contrary, the secondary issue of the nature of innovation is more complicated as it presents a cause and effect relationship with the market scenario.

For a startup's success, it is essential for the product or service to be more 'disruptive' in nature rather than being merely incremental. The startup needs to solve an unsolved problem rather than assisting the problem.

Lessons learned

Now, the million-dollar question is how to learn from 'No Market Need' as the leading startup reason for failure. My advice is to get out and speak early and often with those with a different perspective on the innovation, certainly outside of the area of the innovator. From my experience this is better done in waves in that the questions are asked to the relevant persons, first reaching out to those most proximate to but outside the invention and inception space. After that moving further out from the center to find reason, logic, and ideas for validation of the disruption that can support the startup momentously.

For example, the technology for Solenic Medical addresses infections on medical implants, which was invented by a pair of university researchers at UT Southwestern. The first is an expert in infectious diseases and the second is a thermal medicine engineer.

In my due diligence research, I first reached out to orthopedic surgeons who perform the implant surgeries and deal with the first challenges of infections that arise. Receiving great feedback, almost too good to be true at first pass, I moved on to a next wave of doctors a little further out. I spoke to an ER doctor, a neurosurgeon, an interventional radiologist, and so forth, which didn't result in the same level of enthusiasm but raised good questions that drove further investigation in the due diligence effort.

From there I moved on to contacts in surgical centers and medical billing experts, further removed from the problem and again less enthusiastic. Less enthusiastic for sure, but none of them raised significant barriers, and some helped refine our understanding of what it would take to get the product to market within facility budgets and medical reimbursement requirements.

The crux here was not in any way to disrespect or discredit the inventor of the invention, but to get a perspective that complements the inventor(s) and validate the technology in multiple dimensions: the customer perspective, the product enabled by the technology, team requirements, funding challenges, all leading to valuable insights on the value of the innovation itself.


Obviously in the case of Solenic Medical, we chose to license that technology and form a company around it because we became confident that there was significant market need worth the challenges of bringing the medical device to market. This is what 'Market Need' is all about. It's about finding the right need at the right time and in the right manner.

------

James Y. Lancaster is the Texas branch manager for Arkansas-based VIC Technology Venture Development. Lancaster, who lives in College Station, oversees business there, in Dallas, and in Houston.

This week's Houston innovators are bringing new exciting things to town. Courtesy photos

3 Houston innovators to know this week

who's who

New and exciting things are coming to town — from a data-focused conference two two startup development organizations announcing a Houston presence. Here are three Houston innovators making it happen in town.

James Y. Lancaster, Texas branch manager of VIC Technology Venture Development

A new venture development company has expanded into Houston with a Texas Medical Center office. Photo courtesy of James Lancaster

An Arkansas-based technology venture development firm had its eyes on Dallas for a Texas expansion, but James Y. Lancaster had a bigger plan. Lancaster, who was named as VIC Technology Venture Development's Texas branch manager, oversees the company's business in Dallas, Houston, and College Station, where he lives. Locally, he will work out of a TMC Innovation Institute office.

"I am excited to be working to TMC member institutions to provide a new avenue for commercializing their technologies, expanding on our fast start in Texas with an exciting opportunity in the Houston innovation ecosystem," Lancaster says in a release.

VIC specializes in taking university-founded research innovations to the marketplace by partnering with technology and business experts at every stage of the process. Read more.

Suzette Cotto, CEO of Innovate Social Media

Houston's DataCon can help prepare business leaders for the digital revolution in AI and machine learning. Photo courtesy of Suzette Cotto

Suzette Cotto, in a guest column for InnovationMap, warns of a not-so-distant future where artificial intelligence and machine learning are a daily business requirement. As companies ready themselves for this digital commonplace, its the C-suite that needs to do some homework in preparation.

DataCon Houston, which takes place on October 10, is one way for C-level execs to get some information. The annual conference brings important concepts around AI and Automation to business leaders, according to Cotto.

"The target audience is not IT professionals, although there will be some in attendance; it's meant primarily to help the C-suite and non-technical leaders know where to begin and where to find that new vocabulary and translative resources," Cotto writes. "AI will affect every person in every business, and we must be ready for the cultural shifts that will come with the technological shifts." Read more.

Ed Bosarge, founder and CEO of Houston Healthspan Innovation Group

Houston millionaire and serial entrepreneur Ed Bosarge has launched a new biotech accelerator. Courtesy of Houston Healthspan Innovation Group

A serial entrepreneur, Ed Bosarge has launched his latest venture. The Houston Healthspan Innovation Group is a biotech startup accelerator for companies in the regenerative medicine industry.

"From day one, Houston Healthspan will play a significant role in shaping Houston's vibrant life sciences scene with its seasoned leadership and state-of-the-art facilities," Bosarge says in a news release. "Houston Healthspan may be a tipping point for the region's life sciences community."

According to the release, the organization has already worked with two companies that have relocated their office to Houston. Read more.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Texas A&M University reveals plans for $546M medical complex in Houston

coming soon

Texas A&M University has announced a new three-building project in the Texas Medical Center that will bring a renovated space for its Engineering Medicine program, student housing, parking, retail, and more.

The $546 million complex will be funded in part by a public-private partnership, according to a news release from the university. The project includes one 18-story building to be purchased and renovated for $145 million, and an additional $401 million will go toward constructing two new buildings.

"The Board of Regents of the Texas A&M University System recognized an opportunity in Houston to help Texans and contribute more to the global medical community," says Elaine Mendoza, chairman of the Board of Regents of the Texas A&M University System, in the news release. "We are eager and fortunate to further enhance the world's greatest medical center through this endeavor."

The first of the three buildings to debut will be the EnMed renovation project at 1020 Holcombe Blvd. This project, which had previously been announced, is expected to deliver by this summer and should be monumental for the already successful program, says Bob Harvey, president and CEO of the Greater Houston Partnership, in a statement.

"Texas A&M's EnMed program fits right into what we are doing in Houston," Harvey says. "Our city has long been recognized as a destination for world-class health care and cutting-edge research, thanks to the incredible institutions in the Texas Medical Center. Houston is also becoming known as an attractive location for both mature and emerging life science and biotech companies. We are, indeed, becoming the 'third coast' for life sciences."

A&M TMC The first of the three buildings is expected to be complete this summer. Photo courtesy of Texas A&M University System

The two new construction buildings will be paid for through public-private partnerships. The student housing building, a 19-story building planned to have 572 units with 704 beds in a 365,000 square-foot space, will be completed by June 2022, according to the release. The building will also include a 3,444-spot parking garage. Students from A&M campuses will get priority housing, but students at other institutions will also be allowed spots if available.

"We saw a need for student housing and medical offices in Houston. Plus, our EnMed students needed the facilities to create the latest medical devices," says Greg Hartman, a vice chancellor at Texas A&M University System and interim senior vice president of the Texas A&M Health Science Center, in a news release. "So, we began the process of expanding the Texas A&M footprint in Houston and I believe the work done by Aggies in Houston will be life-changing for a lot of people."

The third component of the plans includes a 587,000-square-foot, 30-floor Integrated Medical Plaza — another public-private partnership — and it has a June 2023 expected completion. Thirteen of the stories will be parking, and 72,000 square feet of space will be for retail use, while 8,700 square feet will be green space.

According to the release, the developer for the two new construction projects is Houston-based Medistar Corp., which is run by CEO Monzer Hourani. New York-basedAmerican Triple I Partners is on the financing team and was founded by Henry Cisneros, a Texas A&M alumnus.

Representatives from both the school and the city see the potential impact of the complex for medical innovations.

"Last year, Houston had its best year ever in terms of attracting venture capital to the region," Harvey says in his statement on the news. "This program and this facility will provide one more reason for major VCs to give Houston's innovative companies a look – and for talented students, researchers, and entrepreneurs to make Houston their home."

Dr. M Katherine Banks, who serves the university of vice chancellor of engineering and national laboratories at the Texas A&M System, notes in the release how the EnMed program has set up its students for breakthrough medical device innovation.

"I expect to see transformative ideas generated by Texas A&M's broadened presence in Houston," says Dr. Banks in the release.

Houston cancer-fighting researchers granted over $30 million from statewide organization

just granted

The Cancer Prevention and Research Institute of Texas has again granted millions to Texas institutions. Across the state, cancer-fighting scientists have received 55 new grants totaling over $78 million.

Five Houston-area institutions — Baylor College of Medicine, the University of Houston, The University of Texas Medical Branch at Galveston, The University of Texas Health Science Center at Houston, and the The University of Texas MD Anderson Cancer Center — have received around $30 million of that grand total.

"These awards reflect CPRIT's established priorities to invest in childhood cancer research, address population and geographic disparities, and recruit top cancer research talent to our academic institutions," says Wayne Roberts, CPRIT CEO, in a news release. "I'm excited about all the awardees, particularly those in San Antonio, a region that continues expand their cancer research and prevention prowess. San Antonio is poised to have an even greater impact across the Texas cancer-fighting ecosystem."

Four grants went to new companies that are bringing new technologies to the market. Two companies with a presence in Houston — Asylia Therapeutics and Barricade Therapeutics Corp. — received grants in this category.

Last fall, CPRIT gave out nearly $136 million to Texas researchers, and, to date, the organization has granted $2.49 billion to Texas research institutions and organizations.

Here's what recent grants were made to Houston institutions.

Baylor College of Medicine

  • $900,000 granted for Feng Yang's research in targeting AKT signaling in MAPK4-high Triple Negative Breast Cancer (Individual Investigator Award)
  • $897,527 Hyun-Sung Lee's research for Spatial Profiling of Tumor-Immune Microenvironment by Multiplexed Single Cell Imaging Mass Cytometry (Individual Investigator Award)
  • $899,847 for Joshua Wythe's research in targeting Endothelial Transcriptional Networks in GBM (Individual Investigator Award)

University of Houston

  • $890,502 for Matthew Gallagher's research in Transdiagnostic Cognitive Behavioral Therapy for Smokers With Anxiety and Depression (Individual Investigator Research Award for Prevention and Early Detection)
  • $299,953 for Lorraine Reitzel's research in Taking Texas Tobacco Free Through a Sustainable Education/Training Program Designed for Personnel Addressing Tobacco Control in Behavioral Health Settings (Dissemination of CPRIT-Funded Cancer Control Interventions Award)

The University of Texas Medical Branch at Galveston

  • $1,993,096 for Abbey Berenson's research in maximizing opportunities for HPV vaccination in medically underserved counties of Southeast Texas (Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations)

The University of Texas Health Science Center at Houston

  • $900,000 for Melissa Aldrich's research on "Can Microsurgeries Cure Lymphedema? An Objective Assessment" (Individual Investigator Award)
  • $900,000 for John Hancock's research in KRAS Spatiotemporal Dynamics: Novel Therapeutic Targets (Individual Investigator Award)
  • $900,000 for Nami McCarty's research in targeting Multiple Myeloma Stem Cell Niche (Individual Investigator Award)
  • $1.96 million for Paula Cuccaro's research in Expanding "All for Them": A comprehensive school-based approach to increase HPV vaccination through public schools (Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations)

The University of Texas MD Anderson Cancer Center

  • $900,000 for Laurence Court's research in Artificial Intelligence for the Peer Review of Radiation Therapy Treatments
  • $900,000 for John deGroot's research in targeting MEK in EGFR-Amplified Glioblastoma (Individual Investigator Award)
  • $900,000 for Don Gibbons's research in Investigating the Role ofCD38 as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer (Individual Investigator Award)
  • $900,000 for John Heymach's research in Molecular Features Impacting Drug Resistance in Atypical EGFR Exon 18 and Exon 20 Mutant NSCLC and the Development of Novel Mutant- Selective Inhibitors (Individual Investigator Award)
  • $900,000 for Zhen Fan's research in Development of a Novel Strategy for Tumor Delivery of MHC-I-Compatible Peptides for Cancer Immunotherapy (Individual Investigator Award)
  • $900,000 for Jin Seon Im's research in off the shelf, Cord-Derived iNK T cells Engineered to Prevent GVHD and Relapse After Hematopoietic Stem Cell Transplantation (Individual Investigator Award)
  • $900,000 for Jae-il Park's research in CRAD Tumor Suppressor and Mucinous Adenocarcinoma (Individual Investigator Award)
  • $900,000 for Helen Piwnica-Worms's research in Single-Cell Evaluation to Identify Tumor-stroma Niches Driving the Transition from In Situ to Invasive Breast Cancer (Individual Investigator Award)
  • $898,872 for Kunal Rai's research in Heterogeneity of Enhancer Patterns in Colorectal Cancers- Mechanisms and Therapy (Individual Investigator Award)
  • $900,000 for Ferdinandos Skoulidis's research in Elucidating Aberrant Splicing-Induced Immune Pathway Activation in RBMl0-Deficient KRAS-Mutant NSCLC and Harnessing Its Potential for Precision Immunotherapy (Individual Investigator Award)
  • $887,713 for Konstantin Sokolov's research in High-Sensitivity 19F MRI for Clinically Translatable Imaging of Adoptive NK Cell Brain Tumor Therapy (Individual Investigator Award)
  • $900,000 for Liuqing Yang's research in Adipocyte-Producing Noncoding RNA Promotes Liver Cancer Immunoresistance (Individual Investigator Award)
  • $1.44 million for Eugenie Kleinerman's research in Doxorubicin-Induced Cardiotoxicity: Defining Blood and Echocardiogram Biomarkers in a Mouse Model and AYA Sarcoma Patients for Evaluating Exercise Interventions (Individual Investigator Award for Cancer in Children and Adolescents)
  • $2.4 million for Arvind Dasari's research in Circulating Tumor DNA- Defined Minimal Residual Disease in Colorectal Cancer (Individual Investigator Research Award for Clinical Translation)
  • Targeting Alterations of the NOTCH! Pathway in Head and Neck Squamous Cell Carcinoma (HNSCC)(Faye Johnson) - $1.2 million (Individual Investigator Research Award for Clinical Translation)
  • $2.07 million for Florencia McAllister's research in Modulating the Gut- Tumor Microbial Axis to Reverse Pancreatic Cancer Immunosuooression (Individual Investigator Research Award for Clinical Translation)
  • $2 million to recruit Eric Smith, MD, PhD, to The University of Texas MD Anderson Cancer Center from Memorial Sloan Kettering Cancer Center (Recruitment of First-Time, Tenure-Track Faculty Members Award)
  • $2 million for Karen Basen-Engquist's research in Active Living After Cancer: Combining a Physical Activity Program with Survivor Navigation (Expansion of Cancer Prevention Services to Rural and Medically Underserved Populations)


Seed Awards for Product Development Research

  • Houston and Boston-based Asylia Therapeutics's Jeno Gyuris was granted $3 million for its development of a Novel Approach to Cancer Immunotherapy by Targeting Extracellular Tumor- derived HSP70 to Dendritic Cells
  • Houston-based Barricade Therapeutics Corp.'s Neil Thapar was granted $3 million for its development of a First-In-Class Small Molecule, TASIN, for Targeting Truncated APC Mutations for the Treatment of Colorectal Cancer (CRC)

5 most popular innovation stories in Houston this week

What's trending

Editor's note: Houston innovators, a new technology hub space making its debut, and more trended on InnovationMap this week. Plus, what should be done with the Astrodome and four research projects in health care to keep an eye on.

3 Houston innovators to know this week

Austin Rolling, Gabriella Rowe, and Aaron Knape are this week's Houston innovators to know. Photos courtesy

In this weekly roundup of Houston innovators, we find an entrepreneur who created the tech solution he wished he'd had as a salesman, an innovation leader with big goals for The Ion, and a startup founder who's in for a very busy March. Continue reading.

These are 4 medical innovations coming out of Houston institutions

These four medical research projects are ones to watch in Houston. Getty Images

Houston — home to one of the largest medical centers in the world — isn't a stranger when it comes to medical innovations and breakthrough research discoveries. In the latest roundup of research innovations, four Houston institutions are working on innovative and — in some cases — life-saving research projects. Continue reading.

Houston expert: The Astrodome should be reimagined for the future of the energy industry

A Houston real estate expert suggests that the icon that is the Astrodome should be restored to be used for energy conferences and other business needs. Photo courtesy of the city of Houston

Over the past several years, there's been a continuous conversation about the iconic Astrodome and what should be done with it. Dubbed the "Eighth Wonder of the World," Houstonians certainly don't want to see the Astrodome go, as it is a landmark deeply embedded into the hearts and minds of our beloved city.

Ideas have been thrown around, yet none of them seem to stick. The $105 million county-approved plan to renovate and build a multi-story parking garage that was approved under Judge Ed Emmett's court in 2018 has been placed on hold until further notice. Continue reading.

Photos: Houston Methodist opens new hub to showcase health tech of the future

The Center for Innovation at Houston Methodist has opened its new Technology Hub to showcase its efforts to advance digital health. Natalie Harms/InnovationMap

Houston Methodist is regularly exploring new digital health technologies, but, until recently, lacked a proper space to demonstrate their vision for the future of health care. Now, with the Center for Innovation's Technology Hub, the hospital has just that.

The tech hub opened earlier this month in Houston Methodist Hospital in the Texas Medical Center. The 3,500-square-foot tech testing ground was renovated from an 18-room patient wing and showcases new digital health technologies like virtual reality, ambient listening, wearables, voice control, and more. Continue reading.

Houston in-seat ordering app gets rodeo ready, prepares for busy XFL season

A Houston startup just got a huge new client: The Houston Livestock Show and Rodeo. Photo courtesy of sEATz

A Houston startup isn't afraid to take on the 21-day Houston Livestock Show and Rodeo with its in-seat ordering technology.

Houston-based sEATz, through its partnership with Aramark and NRG Stadium, will be serving up stadium food to rodeo goers this year every single night of the show. Rather than be intimidated the size and scale of Rodeo Houston, sEATz, equipped with a recently upgraded app, is ready for the challenge. Continue reading.